Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
Cancer
; 119(21): 3784-7, 2013 Nov 01.
Article
em En
| MEDLINE
| ID: mdl-23921838
ABSTRACT
BACKGROUND:
Despite prophylactic platelet transfusions, bleeding remains a significant problem in thrombocytopenic patients.METHODS:
The antifibrinolytic agent epsilon aminocaproic acid (EACA) was administered to 44 chronically (median duration, 273 days) and severely (platelet count, 8 × 10(9)/L; range, 1 × 10(9)/L-19 × 10(9)/L) thrombocytopenic patients with hematological malignancies. Prophylactic EACA at a dose of 1 g twice daily was orally administered for a median duration of 47 days (range, 7 days-209 days) until the platelet count recovered to > 30; × 10(9) /L. Platelets were only transfused if bleeding occurred.RESULTS:
While receiving EACA, 59% of the patients did not bleed, 25% had 19 episodes of spontaneously resolving minor bleeding that did not require platelet transfusion, and 16% received a median of 4 platelet transfusions (range, 1 transfusion-8 transfusions) for 1 major traumatic and 9 spontaneous grade 2 to grade 3 bleeding (based on the World Health Organization classification of idiopathic thrombocytopenic purpura). No EACA toxicities were noted, and venous thromboses were not observed.CONCLUSIONS:
EACA is well tolerated and is associated with a low risk of major bleeding in patients with hematological malignancies who are experiencing chronic severe thrombocytopenia.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Trombocitopenia
/
Neoplasias Hematológicas
/
Ácido Aminocaproico
/
Hemorragia
/
Antifibrinolíticos
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Geórgia